• News
  • Film and TV
  • Music
  • Tech
  • Features
  • Celebrity
  • Politics
  • Weird
  • Community
  • Advertise
  • Terms
  • Privacy & Cookies
  • LADbible Group
  • LADbible
  • SPORTbible
  • GAMINGbible
  • Tyla
  • UNILAD Tech
  • FOODbible
  • License Our Content
  • About Us & Contact
  • Jobs
  • Latest
  • Topics A-Z
  • Authors
Facebook
Instagram
X
Threads
TikTok
YouTube
Submit Your Content
HIV Vaccine Begins Human Trials

Home> News

Updated 11:35 8 Feb 2022 GMTPublished 16:20 28 Jan 2022 GMT

HIV Vaccine Begins Human Trials

The first doses of an experimental HIV vaccine have been administered this week following years of research.

Emily Brown

Emily Brown

The first doses of an experimental HIV vaccine have been administered this week following years of research.

News about the start of the experimental HIV vaccine antigens trial comes from nonprofit scientific research organisation IAVI and biotechnology company Moderna, which is known for its recent creation of a coronavirus vaccine.

The doses, developed by scientific teams at IAVI and Scripps Research and delivered via Moderna's mRNA technology, were administered yesterday, January 27, as part of a trial at George Washington University School of Medicine and Health Sciences in Washington, DC.

Advert

Vaccine (Alamy)
Vaccine (Alamy)

The trial involves 56 healthy, HIV-negative adults, 48 of which will receive one or two doses, with 32 then receiving a boost. An additional eight will receive the booster jab alone, ABC News reports. After receiving the doses, participants are set to be monitored for at least six months while their immune responses are examined in molecular detail.

Development of the vaccine antigens comes after 'years of work' by IAVI and Scripps Research, according to a press release, which explains the first phase is 'designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development'.

The induction of bnAb is 'widely considered to be a goal of HIV vaccination', the creators explain, with the beginning of the trial described as 'the first step in that process'.


Advert

The vaccines were developed with support from the Bill & Melinda Gates Foundation, the Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at the National Institute of Allergy and Infectious Diseases, and Moderna.

Mark Feinberg, president and CEO of IAVI, described the team as being 'tremendously excited to be advancing this new direction in HIV vaccine design with Moderna's mRNA platform'.

Feinberg said the search for an HIV vaccine has been 'long and challenging', and noted that 'having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine'.

He added: 'We are grateful to all of our partners and especially to the Bill & Melinda Gates Foundation for funding this trial.'


Advert

Meanwhile, Moderna president Stephen Hoge said: 'We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the setting of HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world.

'We believe advancing this HIV vaccine program in partnership with IAVI and Scripps Research is an important step in our mission to deliver on the potential for mRNA to improve human health,' he continued.

IAVI and Scripps Research are set to continue the collaboration as they 'extend and evaluate the sequence of promising immunogens to elicit bnAbs'.

If you have a story you want to tell, send it to UNILAD via [email protected]  

Featured Image Credit: Alamy

Topics: Life, Health, Science

Emily Brown
Emily Brown

Emily Brown is UNILAD Editorial Lead at LADbible Group. She first began delivering news when she was just 11 years old - with a paper route - before graduating with a BA Hons in English Language in the Media from Lancaster University. Emily joined UNILAD in 2018 to cover breaking news, trending stories and longer form features. She went on to become Community Desk Lead, commissioning and writing human interest stories from across the globe, before moving to the role of Editorial Lead. Emily now works alongside the UNILAD Editor to ensure the page delivers accurate, interesting and high quality content.

Advert

Advert

Advert

  • The world's first drug that can regrow teeth has been approved for human trials this year
  • Scientists develop world's first ovarian cancer vaccine that 'could wipe the disease out'
  • Scientist issues warning as common hygiene mistake could lead to life-threatening heart condition
  • Scientists accidentally discovered a whole new organ in the human body

Choose your content:

2 hours ago
3 hours ago
  • 2 hours ago

    Everything we know so far after 'new Baba Vanga' predicts catastrophic event as tourists cancel trips

    Apparently tourism has taken a hit in Japan as a result of the worrying forecast for July

    News
  • 3 hours ago

    Woman who thought she would die during shark attack describes the horrifying moments before she was bitten

    Actual nightmare material...

    News
  • 3 hours ago

    Scientists discover sitting for hours actually shrinks the brain in disturbing new study

    You might want to get up and walk around to read this

    News
  • 3 hours ago

    Woman who went viral for using 'clear phone' that left people shocked reveals what it really is

    She said that using the unusual device was 'empowering'

    News